Literature DB >> 9261935

A case of a non-insulin dependent diabetic patient with regular spontaneous hypoglycemic attacks, which were due to insulin-binding antibodies induced by human insulin therapy.

K Suzuki1, S Hirayama, S Ito.   

Abstract

A 74-year-old diabetic patient had been treated with oral hypoglycemic agents from the age of 40 years until the age of 72, when his treatment regimen was changed to human insulin. He began experiencing hypoglycemic attacks 14 months after the initiation of insulin therapy. He continued to experience hyperglycemia every morning and hypoglycemia every day at 5:30 p.m. even after insulin therapy was withdrawn. His plasma levels of C-peptide immunoreactivity, total and free immunoreactive insulins were 4.2 ng/ ml, 740 microU/ml and 141.8 microU/ml, respectively. His 125I-insulin binding rate was 94.4%. These findings suggest that his hypoglycemic attacks may have been due to insulin antibodies. Analysis revealed that insulin binding antibodies belonged to IgG with kappa light chains. The patient's genotype was HLA-DR4. He had not received animal insulin or any medications containing a sulfhydryl group. Although the IgG antibody was produced against injected human insulin, his HLA type and the characteristics of his antibodies resembled those of a patient with insulin autoimmune syndrome (IAS). We hypothesize that this patient represented a rare instance of a patient constitutionally similar to a patient with IAS, but whose hypoglycemic attacks resulted from the antibodies induced by the administration of human insulin. This case seems to be the first one with hypoglycemic attacks due to anti-human insulin antibody produced by human insulin therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261935     DOI: 10.1620/tjem.182.163

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  8 in total

1.  Insulin-induced autoimmune syndrome: A case report.

Authors:  Jian-Ping Chu; Xiao-Wei Zheng; Jie Lu; Jin-Yan Zhong; Jia-Lin Li; Miao Xu; Fang Lin
Journal:  Exp Ther Med       Date:  2016-10-03       Impact factor: 2.447

2.  Frequent reoccurrence of hypoglycemia in a type 2 diabetic patient with insulin antibodies.

Authors:  Tie-Yun Zhao; Fang Li; Zhong-Yun Xiong
Journal:  Mol Diagn Ther       Date:  2010-08-01       Impact factor: 4.074

3.  Successful control of a case of severe insulin allergy with liraglutide.

Authors:  Daiji Kawanami; Tomoko Ito; Yui Watanabe; Jun Kinoshita; Masaya Sakamoto; Tsuyoshi Isaka; Kazunori Utsunomiya
Journal:  J Diabetes Investig       Date:  2012-08-30       Impact factor: 4.232

4.  Immunological hypoglycemia associated with insulin antibodies induced by exogenous insulin in 11 Chinese patients with diabetes.

Authors:  Heng Quan; Huiwen Tan; Qianrui Li; Jianwei Li; Sheyu Li
Journal:  J Diabetes Res       Date:  2015-04-15       Impact factor: 4.011

Review 5.  Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients.

Authors:  Xiaolei Hu; Fengling Chen
Journal:  Endocr Connect       Date:  2017-12-12       Impact factor: 3.335

6.  Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report.

Authors:  Yuko Matsumoto; Hodaka Yamada; Shunsuke Funazaki; Daisuke Suzuki; Masafumi Kakei; Kazuo Hara
Journal:  Diabetes Ther       Date:  2017-08-23       Impact factor: 2.945

7.  Insulin autoimmune syndrome: Three case reports.

Authors:  Fangyuan Chen; Jianming Yang; Yanqun Liu; Wen Wang; Li Zhu; Wei Wang; Jun Yang; Wei You
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

8.  Exogenous insulin antibody syndrome treated with plasma exchange after an incomplete response to immunosuppressive therapy.

Authors:  Yuan Zhuang; Xudong Wei; Yang Yu; Deqing Wang
Journal:  J Clin Apher       Date:  2021-05-20       Impact factor: 2.821

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.